In conclusion, the results suggest that in patients with TTF‐1‐negative NSCLC, continuing PEM therapy without dose reduction after the second cycle, combined with bevacizumab, improve disease control and prolong maintenance treatment and survival. Here, RHOH is linked to non-small cell lung carcinoma.